TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9544892
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (non-steroid treated)
Study: 8290193
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (100 micrograms at induction, 25 micrograms boluses after 45 and 90 minutes)
Study: 8290193
Drug: Oral piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral piroxicam (40 mg)
Study: 6985729
Drug: 5FU +
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU + Mito C (20 mg/m2 IV bolus every 8 weeks)
Study: 6985729
Drug: 5FU +
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU + MeCCNU (150 mg/m2 orally every 8 weeks)
Study: 30203746
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of zoledronic acid combined with oral medication of cinobufagin
Study: 24976202
Drug: Albendazole and
Normalized name: Albendazole and ivermectin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole and antiepileptics
Study: 24976202
Drug: Antiepileptics only
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptics only (Control)
Study: 20814335
Drug: Quercetin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (2000 mg)
Study: 16038841
Drug: Balneotherapy (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (BT) + 1000 mg naproxen (NSAID)
Study: 16038841
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg naproxen (NSAID)
Study: 7853167
Drug: OPC-31260 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-31260 (3, 15, 30, 60, 100, and 200 mg)
Study: 7853167
Drug: OPC-31260 (60-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-31260 (60-200 mg)
Study: 7853167
Drug: OPC-31260 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-31260 (100 and 200 mg)
Study: 7853167
Drug: OPC-31260 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-31260 (200 mg)
Study: 1955232
Drug: levamisole 5
Normalized name: levamisole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole 5 mg/kg body weight on 3 consecutive days every 2 weeks for a period up to 5 months
Study: 6816006
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 25 or 50 mg/kg body weight twice a day for 5 days
Study: 6816006
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V 25 mg/kg body weight twice a day for 10 days
Study: 31818723
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (N = 35)
Study: 31818723
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) (N = 30)
Study: 30385543
Drug: Daily work
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily work breaks in a hospital-integrated garden
Study: 19614689
Drug: PGI(2) (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGI(2) (10 ng kg(‐1) min(‐1) infusion over 25 min)
Study: 17427824
Drug: Excite bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excite bonding agent with light activation
Study: 17427824
Drug: One‐Step bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐Step bonding agent with light activation
Study: 17427824
Drug: Excite DSC
Normalized name: chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Excite DSC bonding agent with light activation
Study: 12442921
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and methotrexate
Study: 2137644
Drug: Chondroprotective agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroprotective agents
Study: 2137644
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of OA of the knee
Study: 382152
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg t.d.s.
Study: 24906585
Drug: Aromatherapy massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy massage (40 min, twice per week for 4 weeks)
Study: 24906585
Drug: Aromatherapy massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy massage (one-time treatment)
Study: 20307214
Drug: Tacrolimus ophthalmic
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ophthalmic suspension 0.1%
Study: 7771913
Drug: Methylphenidate hydrochloride,
Normalized name: Methylphenidate Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride, 1.0 mg/kg per day
Study: 2125153
Drug: Rifampicin, streptomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3)
Study: 2125153
Drug: The same
Normalized name: This Is The Same Medication Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same regimen as R3 followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5)
Study: 28645997
Drug: Antibiotic-containing elastomeric
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-containing elastomeric infusion devices
Study: 23225237
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg daily plus advice for exercise and lifestyle modification
Study: 11101186
Drug: Dry powder
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder fluticasone propionate 200 microg once daily (QD)
Study: 11101186
Drug: Dry powder
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder fluticasone propionate 100 microg twice daily (BID)
Study: 9298513
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg daily, PO)
Study: 20622656
Drug: ONS (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS (oral nutritional supplement)
Study: 8919902
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% at a dose of 0.5-1.0 mg/kg for spinal anesthesia
Study: 1748115
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no antibiotic prophylaxis)
Study: 25403163
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous cardiosphere‐derived cells (CDCs)
Study: 23076005
Drug: Local tumescent
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local tumescent anaesthesia 0.15% TLA: ropivacaine, lidocaine, saline solution plus epinephrine 1:1,000,000
Study: 21781649
Drug: Roflumilast (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast (500 μg, p.o.)
Study: 19303273
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg, three times daily for four weeks)
Study: 19303273
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin placebo, three times daily for four weeks)
Study: 15025736
Drug: RWJ‐68023 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ‐68023 (high dose)
Study: 15025736
Drug: RWJ‐68023 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ‐68023 (low dose)
Study: 9745191
Drug: Isosorbide in
Normalized name: Product containing isosorbide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide in spray 1.25 mg
Study: 9745191
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 4 g infused in one hour, then 1 g each hour for a maximum of five hours
Study: 8521205
Drug: Intravenous chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chlorpromazine (CPZ) 0.1 mg/kg/dose, up to three doses
Study: 8521205
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (MC) 0.1 mg/kg/dose, up to three doses
Study: 8521205
Drug: Intravenous chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous chlorpromazine (CPZ)
Study: 8521205
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (MC)
Study: 30726862
Drug: Glucose 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 2.5 g/day (g-group) for college students
Study: 30726862
Drug: Sucrose 5
Normalized name: SENNA EXT 75ML/SUCROSE 50GM/75ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 5 g/day (s-group) for college students
Study: 30726862
Drug: Fructose 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose 2.5 g/day (f-group) for adults
Study: 30726862
Drug: Sucrose 5
Normalized name: SENNA EXT 75ML/SUCROSE 50GM/75ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 5 g/day (s-group) for adults
Study: 9347592
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic
Study: 8409337
Drug: Roferon A
Normalized name: Roferon A 3million unit/ml Solution for Injection
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roferon A 3 MU administered subcutaneously 3 times weekly after hemodialysis for 6 months
Study: 8409337
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously 3 times weekly after hemodialysis for 6 months
Study: 30102825
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (4 μg/kg/minute for a median duration of 6.0 hours)
Study: 24384643
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day) + ASA (325 mg/day)
Study: 24384643
Drug: ASA (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (325 mg/day)
Study: 12022539
Drug: Celsior solution
Normalized name: Fraxinus excelsior leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior solution for cardiac preservation
Study: 7557846
Drug: daily IFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily IFN‐alpha
Study: 31683483
Drug: Chlorogenic Acids
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic Acids (CGA) beverage (553.6 mg/bottle) twice daily for 12 weeks
Study: 25542620
Drug: Active care
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active care (step-up treatment for recurrence)
Study: 25542620
Drug: Active care
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active care (no change in therapy)
Study: 21725881
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium aescinate (5 mg)
Study: 21725881
Drug: High-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sodium aescinate (10 mg)
Study: 14990784
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (10 mg/day for 48 weeks)
Study: 8317315
Drug: Indomethacin (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (topical pretreatment)
Study: 3027836
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole (200 mg once daily for five consecutive days)
Study: 3027836
Drug: 2.5% selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% selenium sulfide shampoo (once daily application for seven days)
Study: 25044383
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline 400 mg/thrice-weekly
Study: 21081728
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus sorafenib (60 mg/m² doxorubicin every 21 days + 400 mg sorafenib twice daily)
Study: 21081728
Drug: Doxorubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin alone (60 mg/m² doxorubicin every 21 days + placebo)
Study: 6314661
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (surgical and drug therapy including CCNU)
Study: 6314661
Drug: Levomycetin as
Normalized name: Levomycetin
DrugBank: Chloramphenicol (DB00446)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomycetin as part of combined therapy
Study: 6314661
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cancer patients not receiving combined therapy)
Study: 30797722
Drug: Mobile device
Normalized name: blood-glucose meter,for mobile device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile device application (app) for drug preparation
Study: 30797722
Drug: Infusion‐rates table
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion‐rates table
Study: 27869312
Drug: Biofeedback‐assisted pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback‐assisted pelvic muscle therapy (BAPFMT) with the MAPLe
Study: 25476993
Drug: Low-dose total
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose total skin electron beam therapy (12 Gy, 1 Gy per fraction over 3 weeks)
Study: 21707601
Drug: Oral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral intervention
Study: 21707601
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (oral+T/K)
Study: 11606448
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg daily for 12 months)
Study: 11606448
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically appearing tablets daily for 12 months)
Study: 9219507
Drug: UFT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT at 12 mg/kg daily for 1 year
Study: 8489058
Drug: Fentanyl at
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl at 1.67 ng/ml
Study: 18958561
Drug: Radiochemotherapy (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy (5-fluorouracil 200 mg/m2/day and 5040 Gy radiotherapy)
Study: 12819941
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) administered as a constant 72-h i.v. infusion every 2 weeks at a dose of 47 microg/m2 per hour
Study: 12819941
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) administered at 59 microg/m2 per hour
Study: 12819941
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) administered at lower doses
Study: 12819941
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) administered at 47 microg/m2 per hour
Study: 12819941
Drug: 9-aminocamptothecin (9-AC)
Normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-aminocamptothecin (9-AC) administered at various dose levels
Study: 9387348
Drug: Physical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical treatment (Group B)
Study: 1432282
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg/dose, given in three doses 8 hours apart, final dose 1 hour before extubation
Study: 30563758
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus manipulation (n=31)
Study: 30563758
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=30)
Study: 25171133
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading of sodium valproate (20 mg/kg oral single-dose on the first day, then 10-15 mg/kg daily)
Study: 25171133
Drug: Intravenous loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous loading of sodium valproate (20 mg/kg intravenous injection on the first day, then 10-15 mg/kg orally)
Study: 25171133
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance administration of sodium valproate (15-20 mg/kg daily from the beginning)
Study: 22351300
Drug: Conventional bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bolus dose atropine (group A)
Study: 22351300
Drug: Rapidly incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly incremental doses of atropine followed by infusion (group B)
Study: 20153039
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil
Study: 16371681
Drug: Group workshops
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group workshops and single one-on-one tutorials with parents, teachers, and providers about the evaluation and treatment of ADHD.
Study: 10453230
Drug: Oral co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-amoxiclav (amoxycilline and clavulanic acid)
Study: 10453230
Drug: Intramuscular ampicilline
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ampicilline (control)
Study: 2649120
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg twice daily increased to 10 mg twice daily after two weeks)
Study: 16703777
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream with tape occlusion
Study: 11845814
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for 12 months
Study: 320061
Drug: Diftalone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diftalone (1,000 mg during the 1st week; 750 mg the 2nd week; 500 mg from the 3rd week on)
Study: 320061
Drug: Phenylbutazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (400 mg during the 1st week; 300 mg the 2nd week; 200 mg from the 3rd week on)
Study: 31439579
Drug: Taselisib combined
Normalized name: Taselisib
DrugBank: Taselisib (DB12108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib combined with tamoxifen (20mg once daily)
Study: 31439579
Drug: Taselisib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib (2 or 4 mg in an intermittent or continuous schedule)
Study: 28927491
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution plus CPAP
Study: 17882839
Drug: Synthetic ligands
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic ligands for Toll‐like receptors
Study: 17882839
Drug: Polycomponent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycomponent vaccine containing antigens of opportunistic bacteria (Immunovac VP‐4)
Study: 15220700
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of d4T
Study: 15220700
Drug: Treatment using
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment using abacavir or zidovudine
Study: 15220700
Drug: Serum transaminases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum transaminases normalization after d4T discontinuation
Study: 9517940
Drug: ABCD (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCD (4 mg/kg of body weight daily) for up to 6 weeks
Study: 7822089
Drug: Steroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (40 mg of prednisone equivalent)
Study: 7822089
Drug: Steroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (40 mg of prednisone equivalent) + Cyclophosphamide (100 mg)
Study: 7822089
Drug: Steroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (40 mg of prednisone equivalent) + Cyclosporine (5 mg/kg)
Study: 7822089
Drug: Combination treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatments (Cyclophosphamide or Cyclosporine)
Study: 31153362
Drug: 4 week
Normalized name: Rheumatrex Dose Pack 8, 4 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 week physiotherapy programme (6-8 sessions) of manual therapy, exercise and upper limb neural unloading tape
Study: 31153362
Drug: Weekly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly phone advice (control)
Study: 28304350
Drug: Functional bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional bread (low in starch, rich in fibers, 7 g/100 g, beta glucan/starch ratio of 7.6:100 g/g)
Study: 16797329
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly, calcium 1 g daily, calcitriol 0.5 mug daily